I.D. |
Technology |
Pat.
No. (LINK TO
USPTO) |
AM-004 |
Use of Synthetic Peptides to Disrupt the
Cytoskeleton |
5,527,773 |
AM-008 |
Engineering Protein Complexes to Display
Massively Multimeric Antigens and Enzymes |
|
AM-009 |
Laser Inducible Promoter System
(LIPS) |
|
AM-011 |
A Novel Method for Infectivity of
Non-infectable Cells by the Semiliki Forest Virus |
|
AM-012 |
Identification of the Gene Causing Familial
Mediterranean Fever |
|
AM-013 |
Inhibition of IL-6 mRNA production
|
|
AM-015 |
Automated dideoxy-fingerprinting for mutation
detection |
|
AM-016 |
Janus Family Kinases and Identification of
Immune Modulators |
|
AM-017 |
Synthesis and secretion of active recombinant
lysosomal enzymes in the liver |
|
AM-020 |
Deacetylase inhibitors as tools to promote
cell differentiation and regeneration |
|
DC-002 |
Synthesis of Lipooligosaccharide based
vaccines for prevention of Moraxella |
|
DC-003 |
Synthesis of lipooligosaccharide based
vaccines for prevention of Neisseria meningitis |
|
DC-005 |
Induction of cell death in breast cancer cells
by anti-TRAIL R2/DR5 antibody |
|
DC-007 |
Human genetic Variants causing inability to
taste bitter substances |
|
DC-008 |
Mechanosensory ion trnsduction channel of hair
cells in inner ear |
|
DC-011 |
Human Taste Receptor Variants |
|
DC-012 |
Cloning of cDNAs encoding Human
gastrin-releasing peptide receptor (GRP-R) |
|
EH-001 |
Diagnostic Methods and Gene Therapy Using
Reagents Dereived from the Human Metastasis Suppresor Gene
KAI-1 |
|
EH-002 |
Mutants Having a Deficit of Functional Steroid
Hormone Receptors |
5,650,550 |
EH-004 |
"BRCA1 Functionally Null Cell Lines, A17T and
A19T" |
|
EH-005 |
V-ha-ras transgenic Tg.Ac mouse as a model for
photocarcinogenesis |
|
EH-007 |
ZZ-1 A Binding Partner for Steroid
Receptors |
|
EH-008 |
An E. Coli System for Isolation of Human and
other Genes on the Basis of Induction of the SOS Response |
|
EH-009 |
Human Lactoferin and Uses
Thereof |
|
EH-011 |
Human Meiosis Expressed |
|
EH-012 |
Ultraselective Opiodmimetic Peptides and
Pharmacological and Therapeutic Uses Thereof |
|
ES-011 |
Human Meiosis Expressed Cyclin A1 in
yeast |
|
ES-012 |
Ultraselective Opiodmimetic Peptides and
Pharmacological and Therapeutic Uses Thereof |
|
ES-013 |
Laboratory Data Acquisition System
(LDAS) |
|
ES-014 |
A method for selective cloning of a targeted
human chromosome region in yeast |
|
ES-015 |
The use of gamma glutamyl transpeptidase
related enzyme (GGT-rel) in the diagnosis and treatment of human lung
cancer |
|
ES-017 |
Radial trnsformation associated recombination
cloning (TAR cloning) |
|
ES-018 |
The use of cardiac glycosides to modulate the
effect of apoptosis inducing drugs |
|
ES-019 |
17Q Linked Breast and Ovarian Cancer
Susceptibiity Gene |
|
ES-020 |
Construction of cDNAs related to purification
and characterization of DNA polymers |
|
ES-021 |
Use of fluid phase endocytosis in screening
for insulin-mimetic and insulin-potential compounds |
|
ES-022 |
Apoliopoprotein E and regulation of response
to cell injury and inflammation |
|
ES-023 |
CCCH proteins as direct binding and
stabilizing agents from Tumor Necrosis Factor Alpha mRNA |
|
ES-024 |
Protein phosphatase inhibitors to up-regulate
salt and fluid secretion in the lung of cystic fibrosis
patients |
|
ES-025 |
FXR activation by bile acids and substances
that suppress cell growth |
|
ES-026 |
The application of protein phosphatase
inhibitors to up-regulate salt and fluids in CF patients |
|
ES-027 |
Cardiac relaxation by pharmacological
stimulation of Kach potassium channels |
|
ES-029 |
Fluorescent Magnesium
Indicators |
|
ES-030 |
Novel Gene Family for the DiphosphoInositol
Polyphosphate Phosphatases (DIPPs) |
|
ES-031 |
Cloning Expression and Diagnosis of Human Cytochrome P450 2C19 |
|
ES-032 |
Tristetraprolin(TTP) inhibitors as agents to
stabilize granulocyte-macrophage |
|
ES-033 |
Method for Modulating Processses Mediated by
Farnesoid Activated Receptors |
|
ES-034 |
Targeting of human genes in chicken B cell
hybrids containing human chromosomes |
|
ES-035 |
Pharmaceutical Compositions Comprising
Clozapine and a Radical Scavenger |
|
ES-036 |
A genetic system in yeast for functional
indentification of human p53 mutations |
|
ES-037 |
A genetic system in yeast for turning p53
mutant protein into a toxin |
|
ES-038 |
Compositions Comprising Vitamin
F |
|
ES-039 |
Anti-Inflamatory Properties of Cytochrome P450
Expoxygenase-Derived Eicosanoids |
|
ES-040 |
Structured combinatorial queries for
characterizing and comparing biological sequence |
|
ES-042 |
Soluble Epoxide Hydrolase Inhibitors as Novel
Therapeutic Agents for Management of Hypertension |
|
ES-043 |
Wild -Type and DNA Polymerase B Null (KO)
Mouse Embryonic Fibroblast Cell Lines |
|
ES-044 |
Distabilizing agents for mRNAs containing
AU-rich regions |
|
ES-045 |
Inhibition of human multidrug resistance
P-glycoprotein 1 by hybdrophobic analogs of the delta-opioned
antagonist |
|
ES-046 |
DMT-TIC DI and Tri-peptidic derivatives and
related compositions and methods of use |
|
ES-047 |
Use of Endogenous Vertebrate Phytase to
Increase Capacity to Utilize phytic Acid in livestock feed |
|
ES-048 |
A Non-Steroidal Anti-Inflammatory Drug related
Gene (NAG-1) and secreted Protein with anti-tumorgenic
properties |
|
ES-049 |
Pharmaceutical Compositions Comprising
Clozapine and a Radical Scavenger |
|
ES-050 |
Gamma-glutamyl transpeptidase
inhibitor |
|
ES-051 |
A Forward Mutational Assay for Use with
PhiX174 Transgenic Mice |
|
ES-052 |
Kits for determining genotype and / or LOH at
the SSLP loci in hybrid study animals |
|
ES-053 |
Methods for the identification of textual and
physical structured query fragment |
|
ES-054 |
A versatile system for in vivo site-directed
mutagenesis with oligonucleotides |
|
ES-057 |
Pedigree Disequillibrium Test
(PDT) |
|
ES-058 |
Conversion of a potent opiod receptor
antagonist into a potent agonist and other related opiod
ligands |
|
ES-060 |
Genetic engineering the nuclear orphan
receptor to confer the drug-responsiveness |
|
ES-063 |
Improved therrapy for asthma, bronchitis andy
cystic fibrosis through altered expression of 1- phosphatase
activity |
|
ES-064 |
A novel RFXZ4 transcript for use in the
diagnosis and prevention of familial congenital hydrocephalus |
|
ES-065 |
An Isolate of Milk Thistle with Potential
Anti-prostrate Cancer and Anti-cholesterol activity |
|
ES-066 |
Mouse model for early onset
cataract. |
|
ES-067 |
Effective activation of poly(A) - specific
ribonuclease (PARN) by tristetraproli (TTP) and related
proteins |
|
ES-068 |
Expression predictor |
|
ES-069 |
Juvenile hormones and other insecticides
modulate ecdysone receptor-dependent transcriptional activity |
|
ES-070 |
Concept for Development of a Molecular
Expression Knowledge Base |
|
ES-071 |
Creating a Knowledge Management System on
Environmental Gene Changes (EGC) |
|
ES-072 |
Immortalization of human uterine leiomyoma
(fibroid) and uterine smooth muscle |
|
HL-005 |
Human Cells Implanted in Non-Human
Animals |
5,238,683 |
HL-017 |
Cross Axis Synchronous Flow- Through Coil
Planet Centrifuge Free of Rotary Seals |
4,714,554 |
HL-062 |
Retroviral Vectors Containing Internal
Ribosome Entry |
|
HL-075 |
A Simple Method To Form A Sharp Elution Peak
Of A Target Solute By Adding A |
5,354,473 |
HL-080 |
ADP-ribosylarginine Hydrolase Clone
(Mammalian) |
|
HL-081 |
Mammalian Muscle NAD: Arginine
ADP-Ribosyltransferase |
5,834,310 |
HL-098 |
Therapeutic Inhibition of Platelet Aggregation
By Nucleophile-Nitric Oxide Comp |
5,185,376 |
HL-100 |
Parvovirus B19 Receptor and Parvovirus B19
Detection |
5,449,608 |
HL-101 |
A Mammalian Guanine Nucleotide-Binding Protein
With An ADP-Ribosylation Factor |
5,386,021
&
5,514,600
|
HL-110 |
Methods for Diagnosis of XSCID and Kits
Thereof |
5,518,880 |
HL-112 |
Increasing the Frequency of Homologous
Recombination |
|
HL-116 |
Adenovirus Mediated Augmentation of Cell
Transfection With Unmodified Plasmid Vectors |
|
HL-121 |
Vector Systems For The Generation of Adeno-
Associated Virus Particles |
|
HL-122 |
Fusion Proteins Containing Adeno-Associated
Virus Rep Protiens |
|
HL-123 |
T-Cell Alloantigen TR6.2 is an NAD
Glycohydrolase |
|
HL-126 |
Use of Growth Factors to Promote Myocardial
Blood Vessel Growth |
|
HL-132 |
VP1 Unique Region Peptides as Parvovirus
Antigens |
|
HL-142 |
Immunosuppression by inhibiting JAK3-IL-2
receptor association |
6,265,160 |
HL-154 |
Constitutive Jak-Stat pathway in HTLV-I
Transformed T-Cells |
|
HL-157 |
A Lymphocyte
ADP-Ribosyltransferase |
|
HL-158 |
The Use of Lectin Cholestryl Acetyltransferase
(LCAT) in the Treatment of Atherosclerosis |
|
HL-159 |
Increased Expression of Alpha1-Antitrypsin in
Expression Vectors |
5,439,824 |
HL-168 |
A Lymphocyte
ADP-Ribosyltransferase |
|
HL-189 |
Inhibition of PrKX, a Novel Protein Kinase,
and the cAMP-Dependent Protein Kinase |
|
HL-202 |
Chromatographic Fractionation of Proteins by
Ammonium Suflate Precipitation |
|
HL-203 |
Nmi is a cofactor for STAT-dependent
signaling |
|
HL-207 |
Cloning of the human nuclear receptor
co-repressor gene |
|
HL-214 |
Discovery of a novel human aminopeptidase
which may regulate cleavage and shedding |
|
HL-218 |
HCDS1 kinase activates breast tumor suppressor
BRCA1 and promote DNA damage repair |
|
HL-222 |
Biotinylated y-glutmyl-cystinyl-glycine
(glutathione) ethyl ester (Bio Gee) |
|
HL-223 |
A Liver-specific ATP-Binding Tranporter Gene
(WHITE3) is putative transporter |
|
HL-234 |
Targeted T Cells Therapy For Human Leukemia:
PR1 Peptide-Stimulated T Cells Selectivity |
|
HL-235 |
Cardiac contraction is optimized through
differential phosphorylation of myosin |
|
HL-236 |
Cloning of a New Murine Type I cytokine
Receptor. |
|
HL-238 |
Identification and purification of pulmonary
hypertensive substance from Group B streptoccus |
|
HL-239 |
Labeling of atherosclerotic plaques with
anti-cholesterol monoclonal antibodies. |
|
HL-241 |
Fanconi Anemia Protein Complex is a Target of
the IKK Signalsome |
|
HL-244 |
Recombinant Mouse Magnesium-Dependent
Phosphatase -1(MDP-1) |
|
HL-249 |
A selenium containing derivative of lipoic
acid. |
|
HL-250 |
Nitric Oxide Inhalation for Improvement in
Blood Flow (Tissue Perfusion) in Patients |
|
HL-251 |
Monoclonal antibody recognizing the iron
regulatory protein-2 (IRP-2) |
|
HL-255 |
A method for identifying genes determining
cellular phenotypes and expression |
|
HL-256 |
The discovery of a population of stem cells in
adult murine skeletal muscle |
|
HL-261 |
The G protein coupled receptor FPRLI as a
target for developing therapeutic agents |
|
HL-265 |
Modified defensins as therapeutic agents in
inflammatory diseases |
|
HL-266 |
Novel mammalian selenium-containing
protein |
|
HL-269 |
Tryptophan as a Functional replacement for
ADP-ribose arginine in recombinant proteins |
|
HL-272 |
IL 21 critically regulates immunoglobulin
production |
|
HL-273 |
Intralumenal toxin binding by factors derived
from natural products. |
|
HL-275 |
Identification of proteins using molecular
weight and accurate aromatic amino acids |
|
HL-276 |
Method for the preparative separation of polar
compounds |
|
HL-277 |
Compositions and methods for inhibiting Group
B streptococcus-induced pulmonary disease |
|
HL-278 |
Detection of mutational frequency in human
bone marrow by sequencing of mitochodria |
|
HL-284 |
Protein knockout by controllable RNAi in cells
and animals |
|
HL-285 |
Endothelial progenitor cells for the diagnosis
and treatment of vascular disease |
|
|
All
inquires should be directed to (301)-402-5579 |
|